Atle Fund Management AB
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed April 25, 2024), Atle Fund Management AB reported 44 stock positions worth $164.4 million. Its top holding was Merck (MRK) at 10.7% of the portfolio, followed by Eli Lilly (LLY, 9.8%) and Unitedhealth (UNH, 6.9%). Compared with Q4 2023, it opened 5 new positions, sold out of 6, added to 29 and reduced 6. The biggest buy was Merck (MRK, shares +104%) and the biggest sale Gilead Sciences (GILD, shares −47%).
- Most Recent 13F
- Q2 2026
- Location
- STOCKHOLM, V7
- CIK
- 0001381843
- Portfolio Value
- $164.4M (Q1 2024)
- SEC Filing
- 0001381843-24-000004 ↗ filed Apr 25, 2024
Holdings Value
Holdings 44 stocks · $164.4M
| MRK Merck & Co. Inc. | 10.74% | 133,741 | $17.6M | Add +103.6% |
| LLY Eli Lilly & Co. | 9.84% | 20,778 | $16.2M | Add +31.5% |
| UNH Unitedhealth Group Inc. | 6.94% | 23,041 | $11.4M | Add +25.2% |
| TMO Thermo Fisher Scientific Inc. | 5.37% | 15,186 | $8.8M | Add +33.0% |
| NBIX Neurocrine Biosciences Inc. | 3.65% | 43,480 | $6.0M | Add +244.6% |
| HRMY Harmony Biosciences Holdings | 3.47% | 170,000 | $5.7M | Add +17.2% |
| SYK Stryker Corp. | 3.30% | 15,154 | $5.4M | Add +18.4% |
| AMGN Amgen Inc. | 3.27% | 18,891 | $5.4M | Add +17.9% |
| ABBV Abbvie Inc. | 3.25% | 29,346 | $5.3M | Add +38.5% |
| BSX Boston Scientific Corp. | 3.23% | 77,401 | $5.3M | Add +19.4% |
| REGN Regeneron Pharmaceuticals | 3.16% | 5,393 | $5.2M | Add +35.5% |
| COR Cencora Inc. | 3.02% | 20,426 | $5.0M | Reduce -47.5% |
| MOH Molina Healthcare Inc. | 3.00% | 12,000 | $4.9M | Reduce -4.0% |
| VRTX Vertex Pharmaceuticals Inc. | 2.87% | 11,295 | $4.7M | Add +23.7% |
| OPCH Option Care Health Inc. | 2.71% | 132,895 | $4.5M | Add +257.0% |
| ELV Elevance Health Inc. | 2.33% | 7,400 | $3.8M | Reduce -22.1% |
| GILD Gilead Sciences Inc. | 2.32% | 52,000 | $3.8M | Reduce -47.5% |
| DXCM Dexcom Inc. | 2.22% | 26,283 | $3.6M | Add +45.6% |
| MIRM Mirum Pharmaceuticals Inc. | 1.88% | 123,000 | $3.1M | New |
| CAH Cardinal Health Inc. | 1.87% | 27,500 | $3.1M | Reduce -42.7% |
| FOLD Amicus Therapeutics Inc. | 1.81% | 252,307 | $3.0M | Add +418.0% |
| FUSN Fusion Pharmaceuticals Inc. | 1.80% | 138,836 | $3.0M | Add +11.1% |
| IONS Ionis Pharmaceuticals Inc. | 1.68% | 63,791 | $2.8M | Add +163.1% |
| IMCR Immunocore Holdings PLC-ADR | 1.62% | 40,899 | $2.7M | Add +422.8% |
| ITCI Intra-Cellular Therapies Inc. | 1.60% | 38,050 | $2.6M | Add +210.7% |
| IQV Iqvia Holdings Inc. | 1.55% | 10,058 | $2.5M | Reduce -2.7% |
| EW Edwards Lifesciences Corp. | 1.44% | 24,775 | $2.4M | Add +19.0% |
| SWAV Shockwave Medical Inc. | 0.94% | 4,751 | $1.5M | Add +34.6% |
| CRBP Corbus Pharmaceuticals Holdi | 0.91% | 38,000 | $1.5M | New |
| CABA Cabaletta Bio Inc. | 0.80% | 77,540 | $1.3M | Add +269.2% |
| ACLX Arcellx Inc. | 0.74% | 17,496 | $1.2M | Add +53.5% |
| KRYS Krystal Biotech Inc. | 0.72% | 6,624 | $1.2M | No change |
| BBIO Bridgebio Pharma Inc. | 0.71% | 37,841 | $1.2M | Add +57.8% |
| EXAS Exact Sciences Corp. | 0.68% | 16,120 | $1.1M | Add +32.6% |
| MRUS Merus NV | 0.67% | 24,325 | $1.1M | No change |
| INSP Inspire Medical Systems Inc. | 0.63% | 4,782 | $1.0M | Add +48.1% |
| CYTK Cytokinetics Inc. | 0.60% | 14,000 | $982K | Add +19.3% |
| MDGL Madrigal Pharmaceuticals Inc. | 0.57% | 3,539 | $945K | Add +39.8% |
| MGNX Macrogenics Inc. | 0.44% | 49,307 | $726K | New |
| AKRO Akero Therapeutics Inc. | 0.38% | 24,432 | $617K | Add +58.3% |
| AUTL Autolus Therapeutics PLC | 0.37% | 96,345 | $615K | No change |
| NAMS Newamsterdam Pharma Co. NV | 0.32% | 22,394 | $530K | New |
| MORF Morphic Holding Inc. | 0.32% | 14,952 | $526K | No change |
| MERSANA THERAPEUTICS INC | 0.27% | 100,000 | $448K | New |
Portfolio Sells Q4 2023 → Q1 2024
| GILD Gilead Sciences Inc. | Reduce -47.5% | 2.32% | −3.96 |
| CNC Centene Corp. | Sold out | 0.00% | −3.60 |
| BMY Bristol-Myers Squibb Co. | Sold out | 0.00% | −3.53 |
| CI The Cigna Group | Sold out | 0.00% | −3.52 |
| COR Cencora Inc. | Reduce -47.5% | 3.02% | −3.24 |
| CAH Cardinal Health Inc. | Reduce -42.7% | 1.87% | −1.92 |
| ELV Elevance Health Inc. | Reduce -22.1% | 2.33% | −1.17 |
| PFE Pfizer Inc. | Sold out | 0.00% | −0.96 |
| AMAM New Ambrx Biopharma Inc. | Sold out | 0.00% | −0.64 |
| MOH Molina Healthcare Inc. | Reduce -4.0% | 3.00% | −0.54 |
| IQV Iqvia Holdings Inc. | Reduce -2.7% | 1.55% | −0.33 |
| PRTA Prothena Corp. PLC | Sold out | 0.00% | −0.24 |
Portfolio Buys Q4 2023 → Q1 2024
| MRK Merck & Co. Inc. | Add +103.6% | 10.74% | +5.13 |
| LLY Eli Lilly & Co. | Add +31.5% | 9.84% | +2.62 |
| NBIX Neurocrine Biosciences Inc. | Add +244.6% | 3.65% | +2.35 |
| MIRM Mirum Pharmaceuticals Inc. | New | 1.88% | +1.88 |
| OPCH Option Care Health Inc. | Add +257.0% | 2.71% | +1.73 |
| FOLD Amicus Therapeutics Inc. | Add +418.0% | 1.81% | +1.27 |
| IMCR Immunocore Holdings PLC-ADR | Add +422.8% | 1.62% | +1.20 |
| ITCI Intra-Cellular Therapies Inc. | Add +210.7% | 1.60% | +0.92 |
| CRBP Corbus Pharmaceuticals Holdi | New | 0.91% | +0.91 |
| FUSN Fusion Pharmaceuticals Inc. | Add +11.1% | 1.80% | +0.86 |
| IONS Ionis Pharmaceuticals Inc. | Add +163.1% | 1.68% | +0.72 |
| ABBV Abbvie Inc. | Add +38.5% | 3.25% | +0.68 |
| TMO Thermo Fisher Scientific Inc. | Add +33.0% | 5.37% | +0.63 |
| DXCM Dexcom Inc. | Add +45.6% | 2.22% | +0.46 |
| MGNX Macrogenics Inc. | New | 0.44% | +0.44 |
| CABA Cabaletta Bio Inc. | Add +269.2% | 0.80% | +0.43 |
| REGN Regeneron Pharmaceuticals | Add +35.5% | 3.16% | +0.42 |
| SWAV Shockwave Medical Inc. | Add +34.6% | 0.94% | +0.41 |
| NAMS Newamsterdam Pharma Co. NV | New | 0.32% | +0.32 |
| SYK Stryker Corp. | Add +18.4% | 3.30% | +0.30 |
| BSX Boston Scientific Corp. | Add +19.4% | 3.23% | +0.29 |
| MERSANA THERAPEUTICS INC | New | 0.27% | +0.27 |
| ACLX Arcellx Inc. | Add +53.5% | 0.74% | +0.25 |
| EW Edwards Lifesciences Corp. | Add +19.0% | 1.44% | +0.20 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +39.8% | 0.57% | +0.12 |
| INSP Inspire Medical Systems Inc. | Add +48.1% | 0.63% | +0.11 |
| AKRO Akero Therapeutics Inc. | Add +58.3% | 0.38% | +0.09 |
| EXAS Exact Sciences Corp. | Add +32.6% | 0.68% | −0.03 |
| VRTX Vertex Pharmaceuticals Inc. | Add +23.7% | 2.87% | −0.04 |
| BBIO Bridgebio Pharma Inc. | Add +57.8% | 0.71% | −0.05 |
| CYTK Cytokinetics Inc. | Add +19.3% | 0.60% | −0.17 |
| HRMY Harmony Biosciences Holdings | Add +17.2% | 3.47% | −0.19 |
| AMGN Amgen Inc. | Add +17.9% | 3.27% | −0.34 |
| UNH Unitedhealth Group Inc. | Add +25.2% | 6.94% | −0.65 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $371.7M | LLY, MRK, JNJ, ABBV, CVS |
| Q1 2026 | 39 | $309.7M | LLY, MRK, TMO, ONC, JNJ |
| Q4 2025 | 39 | $313.4M | LLY, ABBV, MRK, TMO, NBIX |
| Q3 2025 | 38 | $27.0M | LLY, ABBV, NBIX, MRK, TMO |
| Q2 2025 | 37 | $233.7M | LLY, ABBV, BSX, NBIX, MRK |
| Q1 2025 | 37 | $226.5M | LLY, ABBV, UNH, BSX, MRK |
| Q4 2024 | 36 | $210.8M | LLY, UNH, ABBV, BSX, TMO |
| Q3 2024 | 36 | $212.8M | LLY, UNH, MRK, TMO, AMGN |
| Q2 2024 | 38 | $164.0M | LLY, UNH, MRK, TMO, AMGN |
| Q1 2024 | 44 | $164.4M | MRK, LLY, UNH, TMO, NBIX |